Combining Dasatinib and Curcumin to Fight Chemo-Resistant Colon Cancer
Author Information
Author(s): Jyoti Nautiyal, Shailender S Kanwar, Yingjie Yu, Adhip P.N. Majumdar
Primary Institution: Wayne State University
Hypothesis
Can the combination of dasatinib and curcumin effectively inhibit the growth of chemo-resistant colon cancer cells?
Conclusion
The combination therapy of dasatinib and curcumin significantly reduces the cancer stem cell population in chemo-resistant colon cancer cells.
Supporting Evidence
- The combination therapy showed an 80-90% decrease in the expression of cancer stem cell markers.
- Dasatinib and curcumin demonstrated synergistic effects in inhibiting the growth of chemo-resistant colon cancer cells.
- The combination therapy significantly reduced the size of colonospheres formed by chemo-resistant cells.
Takeaway
This study shows that using two medicines together, dasatinib and curcumin, can help fight stubborn colon cancer cells that don't respond to regular treatments.
Methodology
The study used human colon cancer cell lines and APCMin +/- mice to analyze the effects of dasatinib and curcumin on cancer stem cell markers and tumor growth.
Limitations
The study primarily focuses on in vitro and animal models, which may not fully replicate human responses.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website